A Tata Memorial phase 3 randomized trial of 208 patients with oncogene (read: ALK or EGFR)-driven non-small cell lung cancer with asymptomatic brain metastases demonstrated upfront brain radiation decreased intracranial progression at one year (26% → 9%) and two years (50% → 22%) without clearly influencing overall disease trajectory or survival. | Tibdewal, ASCO 2026
